A5061642557- Cutaneous lymphoproliferative disorders research
- Lymphoma Diagnosis and Treatment
- CAR-T cell therapy research
- Cutaneous Melanoma Detection and Management
- Nail Diseases and Treatments
- Cancer Immunotherapy and Biomarkers
- Chronic Lymphocytic Leukemia Research
- Melanoma and MAPK Pathways
- Immunotherapy and Immune Responses
- Autoimmune Bullous Skin Diseases
- Cancer Genomics and Diagnostics
- Fungal Infections and Studies
- Viral-associated cancers and disorders
- Systemic Sclerosis and Related Diseases
- AI in cancer detection
- melanin and skin pigmentation
- Vascular Tumors and Angiosarcomas
- CNS Lymphoma Diagnosis and Treatment
- Radiomics and Machine Learning in Medical Imaging
- Colorectal and Anal Carcinomas
- Medicine and Dermatology Studies History
- Hidradenitis Suppurativa and Treatments
- Syphilis Diagnosis and Treatment
- Renal cell carcinoma treatment
- Medical and Biological Ozone Research
Leiden University Medical Center
2014-2025
Leiden University
2023-2025
Sint Franciscus Gasthuis
2012
The 2016 World Health Organization classification defines diffuse large B-cell lymphoma (DLBCL) subtypes based on Epstein-Barr virus (EBV) infection and oncogenic rearrangements of MYC/BCL2/BCL6 as drivers lymphomagenesis. A subset DLBCL, however, is characterized by activating mutations in MYD88/CD79B. We investigated whether MYD88/CD79B could improve the prognostication DLBCL. In 250 primary were identified allele-specific polymerase chain reaction or next-generation-sequencing, analyzed...
Primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL-LT) and primary follicle center lymphoma (PCFCL) are lymphomas (CBCL) with different clinical characteristics behavior. PCDLBCL-LT is the most aggressive CBCL a relatively poor prognosis. In nodal (DLBCL), rearrangements of MYC gene, especially in combination second hit BCL2 and/or BCL6, double protein expression (DE) adverse prognostic factors. As significance these factors largely unknown, we studied frequency value DE...
TOX (thymocyte selection-associated high-mobility group box) was shown to be aberrantly expressed in mycosis fungoides (MF) and Sézary syndrome (SS) is suggested have additional diagnostic value. However, data on expression other types of cutaneous T-cell lymphoma (CTCL) are scarce it unknown whether only by MF with a CD4(+) CD8(-) phenotype.To investigate various CTCL different phenotypes.Immunohistochemical evaluated 153 skin biopsies 132 patients 60 benign inflammatory dermatoses...
Primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL-LT) and primary follicle center lymphoma with a population of cells (PCFCL-LC) are both lymphomas large-cell morphology (CLBCL) but different clinical characteristics behavior. In systemic not otherwise specified (DLBCL-NOS), gene-expression profiling (GEP) revealed two molecular subgroups based on their cell-of-origin (COO) prognostic significance: the germinal B-cell-like (GCB) subtype activated (ABC) subtype. This study...
Mucosal melanoma (MM) is a rare tumour with poor prognosis. Over the years, immune and targeted therapy have become available improved overall survival (OS) for patients advanced cutaneous (CM). This study aimed to assess trends in incidence of MM Netherlands against background new effective treatments that became melanoma.We obtained information on diagnosed during 1990-2019 from Cancer Registry. The age-standardized rate estimated annual percentage change (EAPC) were calculated over total...
Primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL-LT) is a rare, aggressive lymphoma with 5-year disease-specific survival of only ~55%. Despite high response rates to initial immune-polychemotherapy, most patients experience disease relapse. The genetic evolution primary and relapsed/refractory has scarcely been studied in PCDLBCL-LT patients. Therefore, this retrospective cohort study, 73 primary/pre-treatment biopsies 57 were molecularly characterized triple FISH targeted...